| 000 | 01874 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517130228.0 | ||
| 264 | 0 | _c20170620 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1572-0241 | ||
| 024 | 7 |
_a10.1038/ajg.2016.542 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCash, Brooks D | |
| 245 | 0 | 0 |
_aSafety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. _h[electronic resource] |
| 260 |
_bThe American journal of gastroenterology _c02 2017 |
||
| 300 |
_a365-374 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAbdominal Pain _xchemically induced |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aConstipation _xchemically induced |
| 650 | 0 | 4 |
_aDiarrhea _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadverse effects |
| 650 | 0 | 4 |
_aIrritable Bowel Syndrome _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aPancreatitis _xchemically induced |
| 650 | 0 | 4 |
_aPhenylalanine _xadverse effects |
| 650 | 0 | 4 |
_aReceptors, Opioid, delta _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Opioid, kappa _xagonists |
| 650 | 0 | 4 |
_aReceptors, Opioid, mu _xagonists |
| 650 | 0 | 4 |
_aSpasm _xchemically induced |
| 650 | 0 | 4 |
_aSphincter of Oddi Dysfunction _xchemically induced |
| 700 | 1 | _aLacy, Brian E | |
| 700 | 1 | _aSchoenfeld, Philip S | |
| 700 | 1 | _aDove, Leonard S | |
| 700 | 1 | _aCovington, Paul S | |
| 773 | 0 |
_tThe American journal of gastroenterology _gvol. 112 _gno. 2 _gp. 365-374 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ajg.2016.542 _zAvailable from publisher's website |
| 999 |
_c26670245 _d26670245 |
||